Cargando…

Autoimmune pancreatitis: What we know so far

Autoimmune pancreatitis (AIP) is a rare, often‐missed disease that involves inflammation of the pancreas and strictures of the pancreatic duct. Its prevalence and incidence in the United States remain scarce. The disease has a varied presentation and often mimics pancreatic malignancy, which can mak...

Descripción completa

Detalles Bibliográficos
Autor principal: Masood, Muaaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762623/
https://www.ncbi.nlm.nih.gov/pubmed/35071782
http://dx.doi.org/10.1002/jgh3.12688
_version_ 1784633800711471104
author Masood, Muaaz
author_facet Masood, Muaaz
author_sort Masood, Muaaz
collection PubMed
description Autoimmune pancreatitis (AIP) is a rare, often‐missed disease that involves inflammation of the pancreas and strictures of the pancreatic duct. Its prevalence and incidence in the United States remain scarce. The disease has a varied presentation and often mimics pancreatic malignancy, which can make the diagnosis challenging. Most patients have an excellent response to corticosteroid therapy. Immunomodulators may be used in some cases. Rituximab is an effective, emerging treatment in steroid‐refractory cases. This study aims to review the two distinct types of AIP and provide a detailed analysis of the diagnostic approach and treatment modalities.
format Online
Article
Text
id pubmed-8762623
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wiley Publishing Asia Pty Ltd
record_format MEDLINE/PubMed
spelling pubmed-87626232022-01-21 Autoimmune pancreatitis: What we know so far Masood, Muaaz JGH Open Review Article Autoimmune pancreatitis (AIP) is a rare, often‐missed disease that involves inflammation of the pancreas and strictures of the pancreatic duct. Its prevalence and incidence in the United States remain scarce. The disease has a varied presentation and often mimics pancreatic malignancy, which can make the diagnosis challenging. Most patients have an excellent response to corticosteroid therapy. Immunomodulators may be used in some cases. Rituximab is an effective, emerging treatment in steroid‐refractory cases. This study aims to review the two distinct types of AIP and provide a detailed analysis of the diagnostic approach and treatment modalities. Wiley Publishing Asia Pty Ltd 2021-12-10 /pmc/articles/PMC8762623/ /pubmed/35071782 http://dx.doi.org/10.1002/jgh3.12688 Text en © 2021 The Author. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Masood, Muaaz
Autoimmune pancreatitis: What we know so far
title Autoimmune pancreatitis: What we know so far
title_full Autoimmune pancreatitis: What we know so far
title_fullStr Autoimmune pancreatitis: What we know so far
title_full_unstemmed Autoimmune pancreatitis: What we know so far
title_short Autoimmune pancreatitis: What we know so far
title_sort autoimmune pancreatitis: what we know so far
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762623/
https://www.ncbi.nlm.nih.gov/pubmed/35071782
http://dx.doi.org/10.1002/jgh3.12688
work_keys_str_mv AT masoodmuaaz autoimmunepancreatitiswhatweknowsofar